Nachrichten zur ZYMEWORKS DL-,00001 Aktie

Zymeworks GAAP EPS of -$0.37 beats by $0.12, revenue of $35.58M beats by $16.06M

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Zymeworks Non-GAAP EPS of -$0.34 beats by $0.20, revenue of $35.58M beats by $16.06M

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Will Zymeworks Inc. (ZYME) Report Negative Earnings Next Week? What You Should Know

Zymeworks Inc. (ZYME) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its…

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, May 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…

Zymeworks, Jazz in pact over cancer antibody zanidatamab

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K Zymeworks Inc. For: Apr 18

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K Zymeworks Inc. For: Apr 10

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Zymeworks Inc. (ZYME) Gains As Market Dips: What You Should Know

Zymeworks Inc. (ZYME) closed at $9.41 in the latest trading session, marking a +0.11% move from the prior day....…

Insiderhandel: Insider kauft Aktien von Zymeworks im Wert von 1.600.000$

Ecor1 Capital, LLC - Zehn-Prozent-Eigentümer - Tag der Transaktion: 2023-03-28...…

Zymeworks Inc. (ZYME) Gains But Lags Market: What You Should Know

Zymeworks Inc. (ZYME) closed the most recent trading day at $8.20, moving +0.12% from the previous trading session....…

Zymeworks a buy at Wells Fargo on royalty streams, future milestones

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Zymeworks and Daiichi Sankyo end bispecific antibody deal

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K Zymeworks Inc. For: Mar 17

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Zymeworks Inc. (ZYME) Gains As Market Dips: What You Should Know

Zymeworks Inc. (ZYME) closed at $8.63 in the latest trading session, marking a +1.89% move from the prior day....…

Zymeworks Shares Rise 8% After 4Q Earnings, Revenue Beat

Zymeworks Shares Rise 8% After 4Q Earnings, Revenue Beat...…

Zymeworks gains 11% on Q4 earnings beat; provides update on cancer drug

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Zymeworks Inc. (ZYME) Q4 Earnings and Revenues Beat Estimates

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 0.65% and 8.38%, respectively, for the quarter ended December 2022. Do…

Zymeworks GAAP EPS of $4.65 beats by $2.16, revenue of $402.49M beats by $188.16M

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K Zymeworks Inc. For: Mar 07

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Earnings Preview: Zymeworks

Zymeworks Inc. (ZYME) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Zymeworks Inc. (ZYME) closed at $8.22, marking a -1.91% move from the previous day....…

Zymeworks Inc. (ZYME) Flat As Market Sinks: What You Should Know

Zymeworks Inc. (ZYME) closed the most recent trading day at $8.57, making no change from the previous trading session....…

Zymeworks Inc. (ZYME) to Report Q4 Results: Wall Street Expects Earnings Growth

Zymeworks Inc. (ZYME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming…

Zymeworks Inc. (ZYME) Dips More Than Broader Markets: What You Should Know

Zymeworks Inc. (ZYME) closed the most recent trading day at $8.90, moving -0.22% from the previous trading session....…

Can Zymeworks (ZYME) Beat Expectations This Earnings Season?

In the absence of a marketed product, Zymeworks (ZYME) is expected to provide an update on its pipeline candidates, mainly…

Zymeworks Inc. (ZYME) Stock Sinks As Market Gains: What You Should Know

Zymeworks Inc. (ZYME) closed the most recent trading day at $9.70, moving -1.22% from the previous trading session....…

Zymeworks Inc. (ZYME) Stock Sinks As Market Gains: What You Should Know

Zymeworks Inc. (ZYME) closed at $9.45 in the latest trading session, marking a -0.94% move from the prior day....…

Zymeworks Inc. (ZYME) Dips More Than Broader Markets: What You Should Know

Zymeworks Inc. (ZYME) closed the most recent trading day at $9.78, moving -0.41% from the previous trading session....…

Insiderhandel: Insider kauft Aktien von Zymeworks im Wert von 1.615.095$

Ecor1 Capital, LLC - Zehn-Prozent-Eigentümer - Tag der Transaktion: 2023-01-20...…

Insiderhandel: Insider kauft Aktien von Zymeworks im Wert von 1.367.639$

Ecor1 Capital, LLC - Zehn-Prozent-Eigentümer - Tag der Transaktion: 2023-01-19...…

Jazz Pharma, Zymeworks post 84% overall survival for GIT cancer candidate

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Thinking about buying stock in Zymeworks, CureVac, Apexigen, Gamida Cell, or Xos?

NEW YORK, Jan. 19, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZYME, CVAC, APGN, GMDA, and XOS. To…

Zymeworks shares gain on promising data for cancer drug in development with Jazz Pharmaceuticals

Shares of Zymeworks Inc. ZYME rallied 14% in premarket trading on Thursday after the company and Jazz Pharmaceuticals Inc. JAZZ…

Form 8-K Zymeworks Inc. For: Jan 19

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma

Results presented today at ASCO GI include first overall survival (OS) data for zanidatamab, overall confirmed objective response rate (cORR)…

dpa-AFX ProFeed